Citations

Institution: Mayo Clinic Clear

Showing 10 of 108104 citations.

PET/CT of Cancer Patients: Part 1, Pancreatic Neoplasms
Dibble, Elizabeth H. , Karantanis, Dimitrios, Mercier, Gustavo , Peller, Patrick J., Kachnic, Lisa A. , Subramaniam, Rathan M.

American Journal of Roentgenology | October 24, 2012 | Volume: 199 | Issue: 5 | Pages: 952-967

10.2214/ajr.11.8182 | PMID 23096166 Get It

Dual-Energy CT–Based Monochromatic Imaging
Yu, Lifeng , Yu, Lifeng , Leng, Shuai , McCollough, Cynthia H.

American Journal of Roentgenology | October 24, 2012 | Volume: 199 | Issue: 5_supplement | Pages: S9-S15

10.2214/ajr.12.9121 | PMID 23097173 Get It

Cardiovascular risk factors, cortisol, and amyloid‐β deposition in Alzheimer's Disease Neuroimaging Initiative
Toledo, Jon B. , Toledo, Estefanía , Weiner, Michael W. , Jack, Clifford R. , Jagust, William, Shaw, Leslie M. , Trojanowski, John Q. , Lee, Virginia M.‐Y. , Jack, Clifford R

Alzheimer's & Dementia | October 24, 2012 | Volume: 8 | Issue: 6 | Pages: 483-489

10.1016/j.jalz.2011.08.008 | PMID 23102118 Get It

AbstractBackgroundThere is epidemiological evidence that cardiovascular risk factors (CVRF) also are risk factors for Alzheimer's disease, but there is limited information on this from neuropathological studies, and even less from in vivo studies. Therefore, we examined the relationship between CVRF and amyloid‐β (Aβ) brain burden measured by Pittsburgh Compound B‐positron emission tomography (PiB‐PET) studies in the Alzheimer's Disease Neuroimaging Initiative.MethodsNinety‐nine subjects from the Alzheimer's Disease Neuroimaging Initiative cohort who had a PiB‐PET study measure, apolipoprotein E genotyping data, and information available on CVRF (body mass index [BMI], systolic blood pressure, diastolic blood pressure [DBP], and cholesterol and fasting glucose test results) were included. Eighty‐one subjects also had plasma cortisol, C‐reactive protein, and superoxide dismutase 1 measurements. Stepwise regression models were used to assess the relation between the CVRF and the composite PiB‐PET score.ResultsThe first model included the following as baseline variables: age, clinical diagnosis, number of apolipoprotein ε4 alleles, BMI (P = .023), and DBP (P = .012). BMI showed an inverse relation with PiB‐PET score, and DBP had a positive relation with PiB‐PET score. In the second adjusted model, cortisol plasma levels were also associated with PiB‐PET score (P = .004). Systolic blood pressure, cholesterol, or impaired fasting glucose were not found to be associated with PiB‐PET values.ConclusionIn this cross‐sectional study, we found an association between Aβ brain burden measured in vivo and DBP and cortisol, indicating a possible link between these CVRF and Aβ burden measured by PiB‐PET. These findings highlight the utility of biomarkers to explore potential pathways linking diverse Alzheimer's disease risk factors.
Longitudinal modeling of cognitive aging and the TOMM40 effect
Caselli, Richard J. , Dueck, Amylou C. , Huentelman, Matthew J. , Lutz, Michael W. , Saunders, Ann M. , Reiman, Eric M. , Roses, Allen D., Dueck, A. C.

Alzheimer's & Dementia | October 24, 2012 | Volume: 8 | Issue: 6 | Pages: 490-495

10.1016/j.jalz.2011.11.006 | PMID 23102119 Get It

AbstractBackgroundTOMM40 (translocase of the outer mitochondrial membrane pore subunit) is in linkage disequilibrium with apolipoprotein E (APOE). APOE e4 is linked to long (L; 21–29 T residues) poly‐T variants within intron 6 of TOMM40, whereas APOE e3 can be associated with either a short (S; <21 T residues) or very long (VL; >29 T residues) variant. To assess the possible contribution of TOMM40 to Alzheimer's disease onset, we compared the effects of TOMM40 and APOE genotype on preclinical longitudinal memory decline.MethodsAn APOE e4–enriched cohort of 639 cognitively normal individuals aged 21 to 97 years with known TOMM40 genotype underwent longitudinal neuropsychological testing every 2 years. We estimated the longitudinal effect of age on memory using statistical models that simultaneously modeled cross‐sectional and longitudinal effects of age on the Auditory Verbal Learning Test Long‐Term Memory score by APOE, TOMM40, and the interaction between the two.ResultsThere were significant effects overall for both TOMM40 (linear effect, P = .04; quadratic effect, P = .03) and APOE (linear effect, P = .06; quadratic effect, P = .008), with no significant interaction (P = .63). In a piecewise model, there was a significant TOMM40 effect before age 60 years (P = .009), characterized by flattened test–retest improvement (VL/VL subgroup only) but no significant APOE effect, and a significant APOE effect after age 60 years (P = .006), characterized by accelerated memory decline (e4 carriers) but no significant TOMM40 effect.ConclusionBoth TOMM40 and APOE significantly influence age‐related memory performance, but they appear to do so independently of each other.
Lowering Kilovoltage to Reduce Radiation Dose in Contrast-Enhanced Abdominal CT: Initial Assessment of a Prototype Automated Kilovoltage Selection Tool
Hough, David M., Grant, Katharine L., Fidler, Jeff L. , Yu, Lifeng , Geske, Jennifer R. , Carter, Rickey E. , Raupach, Rainer , Schmidt, Bernhard , Flohr, Thomas , Fletcher, Joel G. , Fidler, Jeff L. , Yu, Lifeng , McCollough, Cynthia H. , Carter, Rickey E , Geske, Jennifer

American Journal of Roentgenology | October 24, 2012 | Volume: 199 | Issue: 5 | Pages: 1070-1077

10.2214/ajr.12.8637 | PMID 23096181 Get It

Baby Boom or Bust … Is 64 the New 57?
Turner, J. , Cole, Daniel J.

Anesthesiology | October 24, 2012 | Volume: 117 | Issue: 5 | Pages: 931-933

10.1097/aln.0b013e3182700e1b | PMID 23095531 Get It

Patient Satisfaction in an Academic Chronic Pain Clinic
Trentman, Terrence L. , Cornidez, Eric, Wilshusen, Laurie , Seamans, David P. , Rosenfeld, David M. , Freeman, John A., Chien, James J., Chang, Yu‐Hui

Pain Practice | October 24, 2012 | Volume: 13 | Issue: 5 | Pages: 372-379

10.1111/papr.12004 | PMID 23094675 Get It

AbstractObjectivesPatient perception of healthcare quality is of growing interest. It has been shown that patient satisfaction is associated with compliance with medical advice and clinical outcome. The 3‐fold purpose of this study was to identify which attributes of the patient–physician interaction most strongly correlated with patients' perceptions of provider quality of care, to identify key drivers that move patients' perception of overall provider quality from “very good” to “excellent,” and to identify features of the pain clinic experience that were most important to patients but were simultaneously perceived as lacking.MethodsRandomized patient satisfaction survey conducted via telephone approximately 3 weeks after the patient's pain clinic visit.ResultsA total of 999 patients participated in the survey over 5 years (estimated response rate 60.2%). Thoroughness, listening, and time spent with the provider were the 3 attributes most strongly associated with the patients' perceptions of provider quality of care, while thoroughness, listening, punctuality, and clear instructions were the drivers of “very good” vs. “excellent” patient perceived overall provider quality. Areas identified for clinic improvement include thoroughness, providing adequate explanations and instructions, and including patient preferences in decision making.ConclusionsThese results may guide pain clinic physicians as they seek to improve patient perceptions of their care and ultimately patient outcomes.
An Unusual Case of Left Atrial Myxoma and Papillary Fibroelastoma
Chaliki, Hari P. , Najib, Mohammad Q. , Ganji, Jhansi L., Click, Roger L., Challa, Suresh

Echocardiography | October 24, 2012 | Volume: 30 | Issue: 1 | Pages: No page available

10.1111/echo.12010 | PMID 23095166 Get It

Mini‐AbstractWe present a case of a 76‐year‐old woman with new‐onset atrial flutter who underwent transesophageal echocardiography, which demonstrated a large left atrial mass consistent with myxoma and a “shimmering” mobile mass on the aortic side of the right coronary cusp, with fronds consistent with a papillary fibroelastoma. Such concurrent primary cardiac tumors of different histology are a rare occurence.
The Safety of Cardiopulmonary Exercise Testing in a Population With High-Risk Cardiovascular Diseases
Skalski, Joseph H. , Allison, Thomas G. , Miller, Todd D.

Circulation | October 24, 2012 | Volume: 126 | Issue: 21 | Pages: 2465-2472

10.1161/circulationaha.112.110460 | PMID 23091065 Get It

Background— Cardiopulmonary exercise testing (CPX) with measurement of peak oxygen uptake (V o 2 ) is a powerful test for assessment and quantification of functional impairment resulting from cardiovascular disease. The safety of CPX has been established in patients with coronary artery disease and congestive heart failure, but clinical use of CPX in other cardiac diseases has been limited, in part because of a paucity of safety data. This study investigates the safety of CPX in a heterogeneous cohort of patients with a wide variety of underlying high-risk cardiac diagnoses. Methods and Results— This single-center retrospective review examined 5060 CPX studies performed in 4250 unique patients, including 1748 (35%) female subjects and 686 (14%) subjects aged ≥75 years. The primary end point was major adverse event during stress testing. The study population included patients with a variety of high-risk cardiac diseases, including congestive heart failure (n=1289, 25.5%), hypertrophic cardiomyopathy (n=598, 11.8%), pulmonary hypertension (n=194, 3.8%), and aortic stenosis (n=212, 4.2%). This patient population generally had severe functional impairment, including 1192 (24%) patients with peak V o 2 <14 mL/kg/min. Eight adverse events occurred during CPX, for an adverse event rate of 0.16%. The most common adverse event (n=6) was sustained ventricular tachycardia. There were no fatal events. Conclusions— CPX is generally a safe procedure, even in a population with underlying high-risk cardiovascular diagnoses.
Phase I and Pharmacologic Trial of Cytosine Arabinoside with the Selective Checkpoint 1 Inhibitor Sch 900776 in Refractory Acute Leukemias
Karp, Judith E. , Thomas, B M , Greer, Jacqueline M., Sorge, Christopher L., Gore, Steven D. , Pratz, Keith W. , Flatten, Karen S., Peterson, Kevin, Schneider, Paula A., Mackey, Karen, Freshwater, Tomoko, McDevitt, Michael A. , Gladstone, Douglas E. , Showel, Margaret M. , Loechner, Sabine, Horowitz, Jo Ann, Isaacs, Randi , Smith, B. Douglas , Levis, Mark J. , Carraway, Hetty E. , Parry, David , Kaufmann, Scott H.

Clinical Cancer Research | October 24, 2012 | Volume: 18 | Issue: 24 | Pages: 6723-6731

10.1158/1078-0432.ccr-12-2442 | PMID 23092873 Get It

Abstract Purpose: Incorporation of cytarabine into DNA activates checkpoint kinase 1 (Chk1), which stabilizes stalled replication forks, induces S-phase slowing, and diminishes cytarabine cytotoxicity. The selective Chk1 inhibitor SCH 900776 abrogates cytarabine-induced S-phase arrest and enhances cytarabine cytotoxicity in acute leukemia cell lines and leukemic blasts in vitro. To extend these findings to the clinical setting, we have conducted a phase I study of cytarabine and SCH 900776. Experimental Design: Twenty-four adults with relapsed and refractory acute leukemias received timed sequential, continuous infusion cytarabine 2 g/m2 over 72 hours (667 mg/m2/24 hours) beginning on day 1 and again on day 10. SCH 900776 was administered as a 15- to 30-minute infusion on days 2, 3, 11, and 12. The starting dose of SCH 900776 was 10 mg/m2/dose. Results: Dose-limiting toxicities consisting of corrected QT interval prolongation and grade 3 palmar-plantar erythrodysesthesia occurred at 140 mg flat dosing (dose level 5, equivalent to 80 mg/m2). Complete remissions occurred in 8 of 24 (33%) patients, with 7 of 8 at 40 mg/m2 or higher. SCH 900776 did not accumulate at any dose level. Marrow blasts obtained pretreatment and during therapy showed increased phosphorylation of H2Ax after SCH 900776 beginning at 40 mg/m2, consistent with unrepaired DNA damage. Conclusions: These data support a randomized phase II trial of cytarabine +/− SCH 900776 at a recommended flat dose of 100 mg (equivalent to 56 mg/m2) for adults with poor-risk leukemias. The trial (SP P05247) was registered at www.clinicaltrials.gov as NCT00907517. Clin Cancer Res; 18(24); 6723–31. ©2012 AACR.